Literature DB >> 27826588

Is stronger better in curing hepatitis C virus infection?

Stanislas Pol1.   

Abstract

Entities:  

Year:  2016        PMID： 27826588      PMCID： PMC5075865          DOI： 10.21037/atm.2016.08.26

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  9 in total

1.  Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders.

Authors:  Kazuaki Chayama; Shoichi Takahashi; Joji Toyota; Yoshiyasu Karino; Kenji Ikeda; Hiroki Ishikawa; Hideaki Watanabe; Fiona McPhee; Eric Hughes; Hiromitsu Kumada
Journal:  Hepatology       Date:  2012-01-30       Impact factor: 17.425

Review 2.  Future treatment of patients with HCV cirrhosis.

Authors:  Marc Bourlière; Asma Khaloun; Claire Wartelle-Bladou; Valérie Oules; Isabelle Portal; Souad Benali; Xavier Adhoute; Paul Castellani
Journal:  Liver Int       Date:  2012-02       Impact factor: 5.828

3.  Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis.

Authors:  Andrew J Muir; Fred Poordad; Jacob Lalezari; Gregory Everson; Gregory J Dore; Robert Herring; Aasim Sheikh; Paul Kwo; Christophe Hézode; Paul J Pockros; Albert Tran; Joseph Yozviak; Nancy Reau; Alnoor Ramji; Katherine Stuart; Alexander J Thompson; John Vierling; Bradley Freilich; James Cooper; Wayne Ghesquiere; Rong Yang; Fiona McPhee; Eric A Hughes; E Scott Swenson; Philip D Yin
Journal:  JAMA       Date:  2015-05-05       Impact factor: 56.272

4.  Preliminary study of two antiviral agents for hepatitis C genotype 1.

Authors:  Anna S Lok; David F Gardiner; Eric Lawitz; Claudia Martorell; Gregory T Everson; Reem Ghalib; Robert Reindollar; Vinod Rustgi; Fiona McPhee; Megan Wind-Rotolo; Anna Persson; Kurt Zhu; Dessislava I Dimitrova; Timothy Eley; Tong Guo; Dennis M Grasela; Claudio Pasquinelli
Journal:  N Engl J Med       Date:  2012-01-19       Impact factor: 91.245

5.  Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032).

Authors:  Fiona McPhee; Amy K Sheaffer; Jacques Friborg; Dennis Hernandez; Paul Falk; Guangzhi Zhai; Steven Levine; Susan Chaniewski; Fei Yu; Diana Barry; Chaoqun Chen; Min S Lee; Kathy Mosure; Li-Qiang Sun; Michael Sinz; Nicholas A Meanwell; Richard J Colonno; Jay Knipe; Paul Scola
Journal:  Antimicrob Agents Chemother       Date:  2012-08-06       Impact factor: 5.191

6.  All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.

Authors:  Michael Manns; Stanislas Pol; Ira M Jacobson; Patrick Marcellin; Stuart C Gordon; Cheng-Yuan Peng; Ting-Tsung Chang; Gregory T Everson; Jeong Heo; Guido Gerken; Boris Yoffe; William J Towner; Marc Bourliere; Sophie Metivier; Chi-Jen Chu; William Sievert; Jean-Pierre Bronowicki; Dominique Thabut; Youn-Jae Lee; Jia-Horng Kao; Fiona McPhee; Justin Kopit; Patricia Mendez; Misti Linaberry; Eric Hughes; Stephanie Noviello
Journal:  Lancet       Date:  2014-07-28       Impact factor: 79.321

7.  Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options.

Authors:  Yoshiyuki Suzuki; Kenji Ikeda; Fumitaka Suzuki; Joji Toyota; Yoshiyasu Karino; Kazuaki Chayama; Yoshiiku Kawakami; Hiroki Ishikawa; Hideaki Watanabe; Wenhua Hu; Timothy Eley; Fiona McPhee; Eric Hughes; Hiromitsu Kumada
Journal:  J Hepatol       Date:  2012-11-23       Impact factor: 25.083

8.  Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.

Authors:  Mark S Sulkowski; David F Gardiner; Maribel Rodriguez-Torres; K Rajender Reddy; Tarek Hassanein; Ira Jacobson; Eric Lawitz; Anna S Lok; Federico Hinestrosa; Paul J Thuluvath; Howard Schwartz; David R Nelson; Gregory T Everson; Timothy Eley; Megan Wind-Rotolo; Shu-Pang Huang; Min Gao; Dennis Hernandez; Fiona McPhee; Diane Sherman; Robert Hindes; William Symonds; Claudio Pasquinelli; Dennis M Grasela
Journal:  N Engl J Med       Date:  2014-01-16       Impact factor: 91.245

9.  Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.

Authors:  Min Gao; Richard E Nettles; Makonen Belema; Lawrence B Snyder; Van N Nguyen; Robert A Fridell; Michael H Serrano-Wu; David R Langley; Jin-Hua Sun; Donald R O'Boyle; Julie A Lemm; Chunfu Wang; Jay O Knipe; Caly Chien; Richard J Colonno; Dennis M Grasela; Nicholas A Meanwell; Lawrence G Hamann
Journal:  Nature       Date:  2010-04-21       Impact factor: 49.962
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.